10月6—8日，CPHI Milan 2026在意大利米兰国际展览中心举行。九洲药业亮相6C58展位，围绕小分子、多肽及制剂领域，展示从早期研发到商业化生产的一体化CDMO服务能力，与全球客户及行业伙伴共探创新药开发与产业化合作。
展台相聚
交流热度持续
展会期间，九洲药业展台吸引了海内外众多新老客户与行业伙伴到访交流。从项目需求沟通到技术方案探讨，从临床阶段生产到商业化供应规划，团队与来访嘉宾围绕不同开发阶段的实际需求展开深入交流。
对于客户而言，每个项目都有不同的起点与挑战。早期开发需要明确可行的工艺路径，临床推进需要灵活衔接生产与供应，走向商业化则对工艺稳定性、质量合规及交付能力提出更高要求。面对面的交流，让双方更充分地了解项目背景、关键节点与技术难点，为后续合作建立清晰的方向。
从研发到生产
让能力回应项目需求
创新药从分子走向市场，需要跨越的不只是规模变化，还有研发、生产、质量与注册之间的多重衔接。客户关心的不仅是某一项技术能否实现，更是工艺能否顺利放大、不同阶段能否有效衔接，以及供应能否跟上项目进度。
本次展会，九洲药业重点展示小分子与多肽开发及GMP生产、制剂开发，以及可规模化的可靠供应解决方案。通过贯通工艺开发、生产放大与商业化制造，将后续生产与质量保障纳入开发维度，支持客户更早识别潜在问题，为项目进入下一阶段做好准备。
依托国际法规与注册支持能力及GMP生产经验，九洲药业为客户统筹技术、质量和供应需求提供支持。原料药与制剂能力的协同，也为开发进度协调、技术转移及注册工作创造更好的衔接条件。
展台之外
延续合作交流
展会期间，九洲药业举办晚宴。在轻松的氛围中，大家延续展台上的话题，分享行业观察、交流项目进展，也进一步增进了彼此的了解。
一次次交流，让合作需求更加清晰；一次次相聚，让长期伙伴关系更加紧密。感谢每一位到访九洲药业展台、参与晚宴的客户与伙伴。期待将米兰的交流延续到后续项目中，以扎实的技术、质量与交付能力，共同推进创新药开发与产业化。
Jiuzhou Pharma Meets Customers and Partners at CPHI Milan 2026
Jiuzhou Pharma is connecting with pharmaceutical and biotech companies at CPHI Milan 2026, held October 6–8 at Fiera Milano. Booth 6C58 has welcomed a steady flow of customers and industry partners, with conversations focused on small molecule and peptide development, GMP manufacturing, drug product formulation and long-term supply.
For drug developers, the questions are practical: Will the process scale? Can manufacturing keep pace with clinical timelines? What needs to be addressed now to prepare for later-stage development and commercial supply?
These questions are central to Jiuzhou Pharma’s discussions at the event. Its integrated CDMO offering connects early-stage R&D, process development, scale-up and commercial manufacturing, helping customers plan across development stages and coordinate the transition from one to the next.
Planning beyond the next milestone
A process that works in the laboratory must also be suitable for manufacturing. As programs advance, decisions around process design, analytical methods and quality requirements can affect both timelines and supply.
Drawing on its GMP manufacturing experience and global regulatory expertise, Jiuzhou Pharma supports customers in considering these requirements during development. Small molecule and peptide capabilities, together with drug product formulation services, provide a broader basis for coordinating development and manufacturing activities.
At CPHI Milan, discussions range from early development challenges to clinical manufacturing needs and commercial supply planning. Meeting in person gives customer and technical teams the opportunity to understand program priorities, examine potential challenges and define next steps.
Continuing the conversation beyond the stand
Jiuzhou Pharma also hosted a dinner during the exhibition, bringing customers and partners together for an evening in Milan. The gathering offered a relaxed setting to reconnect, share perspectives and continue conversations started on the exhibition floor.
Thank you to everyone who visited Booth 6C58 and joined the dinner. The team looks forward to following up on these discussions and exploring how Jiuzhou Pharma can support the next stage of each program.